FILE PHOTO: A Gilead Sciences, Inc. logo is seen outside the company headquarters in Foster City, California, U.S. May 1, 2018. REUTERS/Stephen Lam
(Reuters) – Gilead Sciences Inc said on Thursday its experimental drug to treat scarring of tissue due to nonalcoholic steatohepatitis (NASH) did not meet main goal of a late stage trial.
NASH is a fatty liver disease where fat accumulation and inflammation can lead to scarring, or fibrosis, that impairs liver function.
Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli